David Amsellem
Stock Analyst at Piper Sandler
(3.79)
# 860
Out of 4,667 analysts
134
Total ratings
49.4%
Success rate
8.65%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OPTN OptiNose | Maintains: Overweight | $3 → $1 | $0.37 | +172.48% | 2 | Nov 13, 2024 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $9 → $11 | $8.41 | +30.80% | 4 | Nov 11, 2024 | |
| XERS Xeris Biopharma Holdings | Downgrades: Neutral | $3 | $3.06 | -1.96% | 4 | Nov 11, 2024 | |
| ALKS Alkermes | Reiterates: Overweight | $38 → $37 | $27.91 | +32.57% | 7 | Oct 25, 2024 | |
| INDV Indivior | Reiterates: Overweight | $15 → $16 | $10.58 | +51.23% | 4 | Oct 25, 2024 | |
| COLL Collegium Pharmaceutical | Reiterates: Neutral | $37 | $30.00 | +23.33% | 6 | Oct 11, 2024 | |
| ANIP ANI Pharmaceuticals | Initiates: Overweight | $68 | $55.10 | +23.41% | 1 | Oct 11, 2024 | |
| CORT Corcept Therapeutics | Maintains: Overweight | $38 → $67 | $56.09 | +19.45% | 5 | Sep 18, 2024 | |
| SUPN Supernus Pharmaceuticals | Downgrades: Neutral | $41 → $36 | $36.12 | -0.33% | 15 | Sep 11, 2024 | |
| NBIX Neurocrine Biosciences | Upgrades: Overweight | $131 → $159 | $123.29 | +28.96% | 8 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $6 | $3.80 | +57.89% | 9 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $66 | $44.09 | +49.69% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $8.19 | -63.37% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $188 → $166 | $119.24 | +39.22% | 10 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $17.03 | +146.62% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $19 → $20 | $17.03 | +17.44% | 9 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $24 | $14.73 | +62.93% | 5 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $4.74 | +111.19% | 1 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $11 → $13 | $13.13 | -0.99% | 5 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $23 | $10.75 | +113.95% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $3.52 | +496.59% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $113 | $94.60 | +19.45% | 3 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $1 | $0.31 | +227.87% | 3 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $32.79 | +28.09% | 3 | Oct 16, 2023 |
OptiNose
Nov 13, 2024
Maintains: Overweight
Price Target: $3 → $1
Current: $0.37
Upside: +172.48%
Amneal Pharmaceuticals
Nov 11, 2024
Maintains: Overweight
Price Target: $9 → $11
Current: $8.41
Upside: +30.80%
Xeris Biopharma Holdings
Nov 11, 2024
Downgrades: Neutral
Price Target: $3
Current: $3.06
Upside: -1.96%
Alkermes
Oct 25, 2024
Reiterates: Overweight
Price Target: $38 → $37
Current: $27.91
Upside: +32.57%
Indivior
Oct 25, 2024
Reiterates: Overweight
Price Target: $15 → $16
Current: $10.58
Upside: +51.23%
Collegium Pharmaceutical
Oct 11, 2024
Reiterates: Neutral
Price Target: $37
Current: $30.00
Upside: +23.33%
ANI Pharmaceuticals
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $55.10
Upside: +23.41%
Corcept Therapeutics
Sep 18, 2024
Maintains: Overweight
Price Target: $38 → $67
Current: $56.09
Upside: +19.45%
Supernus Pharmaceuticals
Sep 11, 2024
Downgrades: Neutral
Price Target: $41 → $36
Current: $36.12
Upside: -0.33%
Neurocrine Biosciences
Aug 29, 2024
Upgrades: Overweight
Price Target: $131 → $159
Current: $123.29
Upside: +28.96%
Aug 9, 2024
Maintains: Overweight
Price Target: $11 → $6
Current: $3.80
Upside: +57.89%
Aug 8, 2024
Maintains: Overweight
Price Target: $71 → $66
Current: $44.09
Upside: +49.69%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $8.19
Upside: -63.37%
Aug 1, 2024
Maintains: Overweight
Price Target: $188 → $166
Current: $119.24
Upside: +39.22%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $17.03
Upside: +146.62%
May 13, 2024
Reiterates: Overweight
Price Target: $19 → $20
Current: $17.03
Upside: +17.44%
Apr 29, 2024
Maintains: Overweight
Price Target: $22 → $24
Current: $14.73
Upside: +62.93%
Apr 11, 2024
Initiates: Overweight
Price Target: $10
Current: $4.74
Upside: +111.19%
Mar 28, 2024
Reiterates: Neutral
Price Target: $11 → $13
Current: $13.13
Upside: -0.99%
Mar 5, 2024
Maintains: Overweight
Price Target: $18 → $23
Current: $10.75
Upside: +113.95%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $3.52
Upside: +496.59%
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $94.60
Upside: +19.45%
Nov 14, 2023
Downgrades: Neutral
Price Target: $12 → $1
Current: $0.31
Upside: +227.87%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $32.79
Upside: +28.09%